Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2025-12-30 @ 7:13 AM
Study NCT ID:
NCT04663867
Status:
COMPLETED
Last Update Posted:
2024-11-04
First Post:
2020-12-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'releaseDate': '2025-12-22'}], 'estimatedResultsFirstSubmitDate': '2025-12-22'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D058729', 'term': 'Peripheral Arterial Disease'}], 'ancestors': [{'id': 'D050197', 'term': 'Atherosclerosis'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D016491', 'term': 'Peripheral Vascular Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 133}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-03', 'type': 'ACTUAL'}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2023-06-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-31', 'studyFirstSubmitDate': '2020-12-01', 'studyFirstSubmitQcDate': '2020-12-05', 'lastUpdatePostDateStruct': {'date': '2024-11-04', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-12-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-04-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical Success of AngioSafe Peripheral CTO Crossing System', 'timeFrame': '24 Hours', 'description': 'Defined as the ability of catheter to facilitate placement of a guidewire into the distal lumen in the absence of device-related major adverse events through discharge or 24-hours post-procedure, whichever is sooner.'}], 'secondaryOutcomes': [{'measure': 'Technical Success of AngioSafe Peripheral CTO Crossing System', 'timeFrame': 'Procedure', 'description': 'Defined as the ability of catheter to facilitate placement of a guidewire into the distal lumen.'}, {'measure': 'Procedural Success of AngioSafe Peripheral CTO Crossing System', 'timeFrame': '30 Days', 'description': 'Defined as the ability of catheter to facilitate placement of a guidewire into the distal lumen without a procedural complication within 30 days after the procedure. Procedural complication is defined as the need for open or repeat endovascular surgical repair in the treated limb, or a major bleeding event.'}, {'measure': 'Evaluation of intraluminal CTO crossing facilitated by the Peripheral CTO Crossing System, as assessed by an Intravascular Ultrasound (IVUS).', 'timeFrame': 'Procedure', 'description': 'Post-procedure IVUS evaluation of technical success cases to determine if crossing was performed intraluminally.'}, {'measure': 'The primary endpoint in the subgroup of the degree of calcification (none/focal/mild/moderate, severe).', 'timeFrame': 'Procedure', 'description': 'Defined as the ability of catheter to facilitate placement of a guidewire into the distal lumen in the absence of device-related major adverse events through discharge or 24-hours post-procedure, whichever is sooner, analyzed by degree of calcification.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Peripheral Artery Occlusion', 'Peripheral Arterial Disease']}, 'descriptionModule': {'briefSummary': 'The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO Crossing System.', 'detailedDescription': 'The purpose of the study is to demonstrate the safety and effectiveness of the AngioSafe Peripheral CTO Crossing System. The system facilitates the crossing of chronic total occlusions (CTOs) in the peripheral arteries of lower limbs. A minimum of 70 subjects will be treated across selected study enters within the U.S. and followed for 30 days.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '22 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Able and willing to comply with protocol requirements and sign informed consent form\n* ≥ 22 years of age\n* Peripheral arterial disease defined by Rutherford Clinical Classification (Category 2-5)\n* Peripheral artery disease in target extremity is confirmed by imaging (catheter angiography, computed tomographic angiography (CTA), and/or magnetic resonance angiography (MRA))\n\nAngiographic Inclusion Criteria:\n\n* Target lesion in native de novo common femoral artery (CFA), superficial femoral artery (SFA), and/or popliteal artery\n* Vessel diameter(s) for target lesion is ≥ 3.0mm and ≤ 10mm\n* Subject's target lesion is a severely stenosed segment of ≤ 300 mm that involves the CTO(s)\n* Subject's target lesion involves at least one CTO that is 99-100% stenosed\n* Subject has at least one vessel with run-off to the foot\n\nExclusion Criteria:\n\n* Systemic infection or an infection in extremity of target lesion\n* Target lesion within native vein or synthetic vessel grafts or in stent occlusion\n* Planned intervention in the contralateral limb during the study\n* Planned intervention in the target limb of the inflow vessels during the study\n* Planned intervention of lower extremities after study procedure within 30-day follow-up visit\n* Coagulopathy or bleeding diatheses, thrombocytopenia with platelet count less than 50,000/μl, or INR \\> 1.7\n* Antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated\n* Allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated\n* Allergy to nickel, titanium, urethane, nylon, or silicone\n* History of myocardial infarction within 30 days prior to enrollment/consent\n* History of stroke within 30 days prior to enrollment/consent\n* Chronic kidney disease (CKD) of stage 4 or greater based on an Estimated Glomerular Filtration Rate (eGFR) \\<30ml/Min, unless the subject is on chronic renal replacement therapy\n* Hemoglobin levels \\<10g/dL verified by a lab test no older than 14 days prior to enrollment, unless the subject has a history of chronic anemia at a stable level, no recent bleeding diathesis or history of blood transfusion in the last six weeks\n* Pregnant or nursing, for females of child-bearing potential (\\< 50 years of age)\n* Participating in another interventional research study that may interfere with study endpoints\n* Prior major amputation (above ankle) in target extremity\n* Acute limb ischemia (ALI)\n* Prior unsuccessful attempt to cross the target lesion\n* Subject has had a procedure on the target limb or contralateral limb within 7 days\n* Subject has had a procedure on the target limb or contralateral limb within the past 30 days and is unstable"}, 'identificationModule': {'nctId': 'NCT04663867', 'acronym': 'RESTOR-1', 'briefTitle': 'AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)', 'organization': {'class': 'INDUSTRY', 'fullName': 'AngioSafe, Inc.'}, 'officialTitle': 'Safety and Effectiveness Study of the AngioSafe Peripheral CTO Crossing System', 'orgStudyIdInfo': {'id': '0071'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'AngioSafe Peripheral CTO Crossing System Procedure', 'description': 'Use of AngioSafe Peripheral CTO Crossing System to facilitate the intraluminal placement of guidewires beyond Chronic Total Occlusions (CTOs) in the peripheral vasculature.', 'interventionNames': ['Device: AngioSafe Peripheral CTO Crossing System']}], 'interventions': [{'name': 'AngioSafe Peripheral CTO Crossing System', 'type': 'DEVICE', 'description': 'The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.', 'armGroupLabels': ['AngioSafe Peripheral CTO Crossing System Procedure']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85224', 'city': 'Chandler', 'state': 'Arizona', 'country': 'United States', 'facility': 'Dignity Health - Chandler Regional Medical Center', 'geoPoint': {'lat': 33.30616, 'lon': -111.84125}}, {'zip': '94754', 'city': 'St. Helena', 'state': 'California', 'country': 'United States', 'facility': 'Adventist Health St. Helena', 'geoPoint': {'lat': 38.50519, 'lon': -122.47026}}, {'zip': '06820', 'city': 'Darien', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Vascular Care Connecticut', 'geoPoint': {'lat': 41.07871, 'lon': -73.46929}}, {'zip': '33140', 'city': 'Miami Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Palm Vascular Centers', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}}, {'zip': '32504', 'city': 'Pensacola', 'state': 'Florida', 'country': 'United States', 'facility': 'Coastal Vascular & Interventional, PLLC', 'geoPoint': {'lat': 30.42131, 'lon': -87.21691}}, {'zip': '30309', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Piedmont Heart Institute', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '52801', 'city': 'Davenport', 'state': 'Iowa', 'country': 'United States', 'facility': 'Midwest Cardiovascular Research Foundation', 'geoPoint': {'lat': 41.52364, 'lon': -90.57764}}, {'zip': '70360', 'city': 'Houma', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Cardiovascular Institute of the South', 'geoPoint': {'lat': 29.59577, 'lon': -90.71953}}, {'zip': '06820', 'city': 'Wellesley', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Vascular Care Group', 'geoPoint': {'lat': 42.29649, 'lon': -71.29256}}, {'zip': '64111', 'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': "Saint Luke's Hospital of Kansas City", 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'zip': '63128', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Mercy Hospital South', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '07052', 'city': 'West Orange', 'state': 'New Jersey', 'country': 'United States', 'facility': 'American Endovascular & Amputation Prevention', 'geoPoint': {'lat': 40.79871, 'lon': -74.23904}}, {'zip': '27518', 'city': 'Cary', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Vascular Solutions of North Carolina', 'geoPoint': {'lat': 35.79154, 'lon': -78.78112}}, {'zip': '02906', 'city': 'Providence', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'The Miriam Hospital', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'zip': '37660', 'city': 'Kingsport', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Wellmont Cardiology Services', 'geoPoint': {'lat': 36.54843, 'lon': -82.56182}}, {'zip': '75216', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'VA North Texas Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75093', 'city': 'Plano', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor Scott & White, The Heart Hospital Plano', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'zip': '75701', 'city': 'Tyler', 'state': 'Texas', 'country': 'United States', 'facility': 'Cardiovascular Associated of East Texas', 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}}], 'overallOfficials': [{'name': 'Subhash Banerjee, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'North Texas Veterans Healthcare System'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AngioSafe, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Veranex, Inc.', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR'}}}}